Biotech uni­corn's 'brain' at­tracts a $115M mega-round as in­vestors em­brace AI up­start

Ar­ti­fi­cial in­tel­li­gence in drug de­vel­op­ment is still gain­ing mo­men­tum. Just ask Benev­o­len­tAI, which has brought in a new $115 mil­lion round for its tech­nol­o­gy that promis­es to process vast amounts of bio­science in­for­ma­tion and churn out new dis­cov­er­ies.

Ken Mul­vany

Backed by new, undis­closed in­vestors from the Unit­ed States as well as ex­ist­ing sup­port­ers like Wood­ford In­vest­ment Man­age­ment, the round puts Lon­don-based Benev­o­len­tAI at a pre-mon­ey val­u­a­tion of $2 bil­lion. The syn­di­cate fea­tures a mix of fam­i­ly of­fices and some strate­gic back­ers but not “more tra­di­tion­al VCs,” TechCrunch re­ports.

Since its found­ing in 2013, the biotech has raised more than $200 mil­lion. The new cash will go in­to scal­ing its drug de­vel­op­ment ac­tiv­i­ties, broad­en­ing fo­cus dis­ease area, and ex­tend its plat­form ca­pa­bil­i­ties — not just in phar­ma­ceu­ti­cals but al­so in ma­te­r­i­al sci­ence, en­er­gy and agri­cul­ture.

De­spite con­tin­ued skep­ti­cism and scruti­ny as to how much AI can shave off the painful­ly lengthy drug de­vel­op­ment process and in­crease suc­cess rates, it con­tin­ues to in­spire en­thu­si­asm es­pe­cial­ly in Big Phar­ma, where ex­ecs are al­ways look­ing for ways to trim spend­ing. In fact, J&J hand­ed some clin­i­cal-stage drug can­di­dates for Benev­o­len­tAI to guide de­vel­op­ment back in 2016 with plans to start Phase IIb tri­als last year.

Jack­ie Hunter

The core of Benev­o­len­tAI’s promise is an AI “brain” that now holds “50 bil­lion bi­o­log­i­cal da­ta points and com­plex bi­o­log­i­cal con­cepts – the world’s largest most so­phis­ti­cat­ed bio­science knowl­edge graph,” founder and chair­man Ken Mul­vany writes in a blog post. “The tech­nol­o­gy that sits on this knowl­edge is able to gen­er­ate new in­sights in­to the cause of dis­ease at a scale not pos­si­ble for hu­man be­ings.”

Un­der the lead­er­ship of GSK vet Jack­ie Hunter, Benev­o­len­tAI is work­ing on 22 pro­grams across ar­eas span­ning Parkin­son’s dis­ease, mo­tor neu­ron dis­ease, glioblas­toma and sar­cope­nia, though on­ly two are in ad­vanced stages.

Re­cent­ly, the com­pa­ny ac­quired a drug dis­cov­ery and de­vel­op­ment fa­cil­i­ty on the Babra­ham Re­search Cam­pus in Cam­bridge, UK, bring­ing a new sci­en­tif­ic team and late-stage clin­i­cal test­ing ca­pa­bil­i­ties in­to its fold. Mul­vany told TechCrunch that he hopes to al­most dou­ble the size of the team by the end of the year, from 155 to 300.

“We have come a very long way since we found­ed the busi­ness in 2013. The ca­pa­bil­i­ties of our tech­nol­o­gy didn’t ex­ist 6 years ago,” he said in a state­ment.

Up­dat­ed: FDA re­mains silent on or­phan drug ex­clu­siv­i­ty af­ter last year's court loss

Since losing a controversial court case over orphan drug exclusivity last year, the FDA’s Office of Orphan Products Development has remained entirely silent on orphan exclusivity for any product approved since last November, leaving many sponsors in limbo on what to expect.

That silence means that for more than 70 orphan-designated indications for more than 60 products, OOPD has issued no public determination on the seven-year orphan exclusivity in the Orange Book, and no new listings of orphan exclusivity appear in OOPD’s searchable database, as highlighted recently by George O’Brien, a partner in Mayer Brown’s Washington, DC office.

Illustration: Assistant Editor Kathy Wong for Endpoints News

As mon­ey pours in­to dig­i­tal ther­a­peu­tics, in­sur­ance cov­er­age crawls



Talk therapy didn’t help Lily with attention deficit hyperactivity disorder, or ADHD. But a video game did.

As the 10-year-old zooms through icy waters and targets flying creatures on the snow-capped planet Frigidus, she builds attention skills, thanks to Akili Interactive Labs’ video game EndeavorRx. She’s now less anxious and scattered, allowing her to stay on a low dose of ADHD medication, according to her mom Violet Vu.

Endpoints Premium

Premium subscription required

Unlock this article along with other benefits by subscribing to one of our paid plans.

Eli Lil­ly’s Alzheimer’s drug clears more amy­loid ear­ly than Aduhelm in first-ever head-to-head. Will it mat­ter?

Ahead of the FDA’s decision on Eli Lilly’s Alzheimer’s drug donanemab in February, the Big Pharma is dropping a first cut of data from one of the more interesting trials — but less important in a regulatory sense — at an Alzheimer’s conference in San Francisco.

In the unblinded 148-person study, Eli Lilly pitted its drug against Aduhelm, Biogen’s drug that won FDA approval but lost Medicare coverage outside of clinical trials. Notably, the study didn’t look at clinical outcomes, but rather the clearance of amyloid, a protein whose buildup is associated with Alzheimer’s disease, in the brain.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 153,900+ biopharma pros reading Endpoints daily — and it's free.

Uğur Şahin, BioNTech CEO (ddp images/Sipa USA/Sipa via AP Images)

BioN­Tech bets on dif­fi­cult STING field via small mol­e­cule pact with a Pol­ish biotech

BioNTech is beefing up its relatively thin small molecule pipeline by adding weight to a clinically difficult corner of oncology R&D: STING agonists. To do so, BioNTech is teaming up with a 15-year-old Polish biotech and doling out €40 million, about $41.5 million, to start.

The deal is broken into two parts: First, BioNTech obtains an exclusive global license to develop and market Ryvu Therapeutics’ STING agonist portfolio as small molecules, whether alone or in combination with other agents.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 153,900+ biopharma pros reading Endpoints daily — and it's free.

Lynn Baxter, Viiv Healthcare's head of North America

Vi­iV dri­ves new cor­po­rate coali­tion in­clud­ing Uber, Tin­der and Wal­mart, aimed at end­ing HIV

ViiV Healthcare is pulling together an eclectic coalition of consumer businesses in a new White House-endorsed effort to end HIV by the end of the decade.

The new US Business Action to End HIV includes pharma and health companies — Gilead Sciences, CVS Health and Walgreens — but extends to a wide range of consumer companies that includes Tinder, Uber and Walmart.

ViiV is the catalyst for the group, plunking down more than half a million dollars in seed money and taking on ringmaster duties for launch today on World AIDS Day, but co-creator Health Action Alliance will organize joint activities going forward. ViiV and the alliance want and expect more companies to not only join the effort, but also pitch in funding.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 153,900+ biopharma pros reading Endpoints daily — and it's free.

Pfiz­er will in­vest $1.2B+ in Irish man­u­fac­tur­ing site, adding 500 em­ploy­ees

Covid-19 trailblazer Pfizer has confirmed its commitment to a large expansion project on the Emerald Isle.

The New York-based company announced on Thursday that it will make a €1.2 billion ($1.26 billion) capital investment into its manufacturing site at Grange Castle in Dublin.

The expansion of the site marks Pfizer’s largest expansion investment in Ireland to date. The expansion includes the construction of a new facility on the premises as well as adding in more laboratory space and will ultimately double the capacity for “biological drug substance manufacturing” in the oncology and rare disease space as well as inflammation, immunology and internal medicines.

In­tel­lia and Iver­ic sell stocks to raise mon­ey, each net­ting $300M

Wednesday afternoon, Gene editing company Intellia and eye disease company Iveric Bio announced that they had each raised $300 million by selling off some of their stocks. The two biotechs are the latest to raise money via public stock offerings, an increasingly popular tactic used by public companies as the industry falls back from its pandemic boom.

Intellia’s raise comes a few weeks after it posted an update on its hereditary angioedema program that uses CRISPR/Cas9 to directly edit the gene that makes the protein responsible for the attacks that occur with the disease. In that interim cut, Intellia showed that patients dosed with its one-time therapy became attack free (at least thus far) after an observation period of 16 weeks, with the longest patient remaining attack free for 10 months.

Matt Gline, Roivant Sciences CEO (Photo by John Sciulli/Getty Images for GLG)

Pfiz­er and Roivant team up again for an­oth­er 'Van­t', set­ting up an­ti-in­flam­ma­to­ry show­down with Prometheus

Pfizer and Roivant are teaming up to launch a new ‘Vant’ aimed at bringing a mid-stage anti-inflammatory drug to market, the pair announced Thursday.

There’s no name for the startup yet, nor are there any employees. Thus far, the new company and Roivant can be considered “one and the same,” Roivant CEO Matt Gline tells Endpoints News. But Pfizer is so enthusiastic about the target that it elected to keep 25% of equity in the drug rather than take upfront cash from Roivant, Gline said.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 153,900+ biopharma pros reading Endpoints daily — and it's free.

Roche HQ in Basel, Switzerland. (Image credit: Kyle LaHucik/Endpoints News)

As com­peti­tors near FDA goal­post, Roche spells out its re­peat Alzheimer's set­back

Before Roche can turn all eyes on a new version of its more-than-once-failed Alzheimer’s drug gantenerumab, the Big Pharma had to flesh out data on the November topline failure at an annual conference buzzier than in years past thanks to hotly watched rivals in the field: Eisai and Biogen’s lecanemab, and Eli Lilly’s donanemab.

There was less than a 10% difference between Roche’s drug and placebo at slowing cognitive decline across two Phase III trials, which combined enrolled nearly 2,000 Alzheimer’s patients. In its presentation at the conference Wednesday, Roche said it saw less sweeping away of toxic proteins than it had anticipated. For years, researchers and investors have put their resources behind the idea that more amyloid removal would equate to reduced cognitive decline.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 153,900+ biopharma pros reading Endpoints daily — and it's free.